NEGXF (NexgenRx) Moat Score: 3/10 (As of Jul. 05, 2026)


NEGXF NexgenRx Inc NEGXF
40 GF Score
Price $0.33
GF Value $0.22
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is NexgenRx Moat Score?

NexgenRx NEGXF 40 Moat Score is 3 as of Jul. 05, 2026. GuruFocus rates NEGXF with a GF Score™ of 40/100 and a GF Value™ of $0.22 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 676 Healthcare Providers & Services companies, NexgenRx ranks better than 84.32% on this metric.

NexgenRx has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

NexgenRx has No Moat: NexgenRx operates in a competitive healthcare services market with limited differentiation. It lacks significant market share, customer switching costs, or proprietary technology, and faces standard regulatory barriers.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes NexgenRx might have No Moat - Very weak/transient advantages.

NexgenRx  (OTCPK:NEGXF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

NexgenRx Moat Score Related Terms

NEGXF vs VEEV, BTSG, TEM: Moat Score Comparison

For the Health Information Services subindustry, NexgenRx's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NexgenRx Moat Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, NexgenRx's Moat Score distribution charts can be found below:

* The bar in red indicates where NexgenRx's Moat Score falls into.


NEGXF
40GF Score
NexgenRx Inc NEGXF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
NexgenRx (NEGXF) has a Moat Score of 3 as of Jul. 05, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, NexgenRx ranks #106 out of 676 companies in the Healthcare Providers & Services industry, placing it in the top 15.7%.
Is NexgenRx's Moat Score too high?
NexgenRx's current Moat Score is 3. Based on the distribution chart, NexgenRx ranks #106 out of 676 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, NexgenRx has a GF Score™ of 40/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NexgenRx's Moat Score compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, NexgenRx ranks #106 out of 676 companies for Moat Score. This places NexgenRx in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Healthcare Providers & Services company?
A good Moat Score depends on the Healthcare Providers & Services industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. NexgenRx's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexgenRx stock overvalued right now?
Based on GuruFocus' analysis, NexgenRx (NEGXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.22, compared to a current price of $0.33 — trading 47.7% above its estimated fair value. The current Moat Score is 3. NexgenRx's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For NexgenRx (NEGXF), the current Moat Score is 3 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NexgenRx (NEGXF) Overvalued in 2026?

Based on GuruFocus' analysis, NexgenRx stock appears to be overvalued. The current stock price of $0.33 is trading 47.7% above its estimated GF Value™ of $0.22. GuruFocus considers NexgenRx to be Modestly Overvalued.

Key valuation signals for NEGXF:

  • Moat Score: 3
  • GF Value™: $0.22 vs. price of $0.33 (47.7% above fair value)
  • GF Score™: 40/100 with 6 warning signs

No single metric tells the full story. See the NEGXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NexgenRx Business Description

Other Exchanges NXG:Canada
Address 191 The West Mall, Suite 905, Toronto, ON, CAN, M9C 5L6
NexgenRx Inc administers, adjudicates, and pays drug, dental and other extended health-care claims for the beneficiaries of health benefit plans underwritten by its customers using proprietary computer software and also provides ancillary services. The various solutions offered by the company include: NexSys, a fully integrated rules-based adjudication platform for real-time processing of drug, dental, and extended health benefit claims; NexAdmin, which enables sponsors to take complete control of benefit plan administration; and NexPSPAssist, a service that helps Patient Support Programs (PSP) to optimize their deliverables to their manufacturer clients. The company has only one operating segment - benefits administration services.
40GF Score

Get the complete analysis for NEGXF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.33
Price
$0.22
GF Value